Oxford Biomedica, a gene and cell therapy group, has amended and expanded the License and Clinical Supply Agreement with Juno Therapeutics, Inc., a wholly owned subsidiary of Bristol Myers Squibb. The amendment relates to the initiation of two new viral vector programs for Bristol Myers Squibb CAR-T therapies.   The agreement, announced in March 2020, granted Juno a non-exclusive license to Oxford Biomedica’s LentiVector platform to be used for the manufacture of viral vectors for CAR-T and TC...